Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

被引：376

作者：

Vilsboll, Tina

Zdravkovic, Milan

Le-Thi, Tu

Krarup, Thure

Schmitz, Ole

Courreges, Jean-Pierre

Verhoeven, Robert

Buganova, Ingrid

Madsbad, Sten

机构：

[1] Gentofte Univ Hosp, Dept Internal Med, DK-2900 Hellerup, Denmark

[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

[3] Aarhus Hosp, Aarhus, Denmark

[4] Ctr Hosp Narbonne, Narbonne, France

[5] Gelre Ziekenhuis, Apeldoorn, Netherlands

[6] Dibetol Ambulancia, Zilina, Slovakia

[7] Hvidovre Univ Hosp, Copenhagen, Denmark

来源：

DIABETES CARE | 2007年 / 30卷 / 06期

关键词：

D O I：

10.2337/dc06-2593

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1608 / 1610

页数：3

共 11 条

[1] Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
Agerso, H
Vicini, P
[J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 (2-3) : 141 - 150
[2] Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[3] One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
Degn, KB
Juhl, CB
Sturis, J
Jakobsen, G
Brock, B
Chandramouli, V
Rungby, J
Landau, BR
Schmitz, O
[J]. DIABETES, 2004, 53 (05) : 1187 - 1194
[4] Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
Knudsen, LB
Nielsen, PF
Huusfeldt, PO
Johansen, NL
Madsen, K
Pedersen, FZ
Thogersen, H
Wilken, M
Agerso, H
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) : 1664 - 1669
[5] Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial
Madsbad, S
Schmitz, O
Ranstam, J
Jakobsen, G
Matthews, DR
[J]. DIABETES CARE, 2004, 27 (06) : 1335 - 1342
[6] Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
Nauck, M. A.
Hompesch, M.
Filipczak, R.
Le, T. D. T.
Zdravkovic, M.
Gumprecht, J.
[J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (08) : 417 - 423
[7] PIPER K, 2005, DIABETOLOGIA, pA394
[8] The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
Rolin, B
Larsen, MO
Gotfredsen, CF
Deacon, CF
Carr, RD
Wilken, M
Knudsen, LB
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04): : E745 - E752
[9] GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics
Sturis, J
Gotfredsen, CF
Romer, J
Rolin, B
Ribel, U
Brand, CL
Wilken, M
Wassermann, K
Deacon, CF
Carr, RD
Knudsen, LB
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (01) : 123 - 132
[10] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Turner, RC
Holman, RR
Cull, CA
Stratton, IM
Matthews, DR
Frighi, V
Manley, SE
Neil, A
McElroy, K
Wright, D
Kohner, E
Fox, C
Hadden, D
Mehta, Z
Smith, A
Nugent, Z
Peto, R
Adlel, AI
Mann, JI
Bassett, PA
Oakes, SF
Dornan, TL
Aldington, S
Lipinski, H
Collum, R
Harrison, K
MacIntyre, C
Skinner, S
Mortemore, A
Nelson, D
Cockley, S
Levien, S
Bodsworth, L
Willox, R
Biggs, T
Dove, S
Beattie, E
Gradwell, M
Staples, S
Lam, R
Taylor, F
Leung, L
Carter, RD
Brownlee, SM
Fisher, KE
Islam, K
Jelfs, R
Williams, PA
Williams, FA
Sutton, PJ
[J]. LANCET, 1998, 352 (9131) : 837 - 853

← 1 2 →